CTAG1B and neoplasm: These results indicate that NY‐ESO‐1, even in tumours that do not naturally express it, could function as an adjuvant, effectively training both innate immune cells and T cells to recognise and target tumour epitopes with increased immunogenicity (Figure 2).57